ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Windtree Therapeutics Inc

Windtree Therapeutics Inc (WINT)

0.592
-0.012
(-1.99%)
0.565
-0.027
(-4.56%)

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
0.565
Bid
0.565
Ask
0.5849
Volume
1,048,181
0.5555 Day's Range 0.628
0.5213 52 Week Range 737.435
Market Cap
Previous Close
0.604
Open
0.58
Last Trade Time
Financial Volume
$ 611,530
VWAP
0.583421
Average Volume (3m)
2,743,793
Shares Outstanding
3,661,289
Dividend Yield
-
PE Ratio
-0.39
Earnings Per Share (EPS)
-1.5
Revenue
-
Net Profit
-5.49M

About Windtree Therapeutics Inc

Windtree Therapeutics Inc is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. Its technology platform includes synthetic, peptide-containing surfactant and novel drug delivery technologies that deliver aerosolized KL4 surfactants with... Windtree Therapeutics Inc is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. Its technology platform includes synthetic, peptide-containing surfactant and novel drug delivery technologies that deliver aerosolized KL4 surfactants without invasive procedures. Its development program utilizing its proprietary technology platform is AEROSURF which is being developed for the treatment of respiratory distress syndrome in premature infants. It operates in the business segment of research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
-
Windtree Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker WINT. The last closing price for Windtree Therapeutics was $0.60. Over the last year, Windtree Therapeutics shares have traded in a share price range of $ 0.5213 to $ 737.435.

Windtree Therapeutics currently has 3,661,289 shares outstanding. The market capitalization of Windtree Therapeutics is $2.21 million. Windtree Therapeutics has a price to earnings ratio (PE ratio) of -0.39.

WINT Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0364-6.052544063850.60141.040.5213239195920.78974362CS
4-0.265-31.92771084340.831.040.521365232480.78835822CS
12-1.335-70.26315789471.92.170.521327437930.9807598CS
26-17.095-96.800679501717.66210.521357372705.93237808CS
52-147.935-99.6195286195148.5737.4350.5213358637740.99820788CS
156-20249.435-99.997209876520250396000.521318155884238.64572569CS
260-301049.435-99.99981232353010504527000.5213135155323362.5993074CS

WINT - Frequently Asked Questions (FAQ)

What is the current Windtree Therapeutics share price?
The current share price of Windtree Therapeutics is $ 0.565
How many Windtree Therapeutics shares are in issue?
Windtree Therapeutics has 3,661,289 shares in issue
What is the market cap of Windtree Therapeutics?
The market capitalisation of Windtree Therapeutics is USD 2.21M
What is the 1 year trading range for Windtree Therapeutics share price?
Windtree Therapeutics has traded in the range of $ 0.5213 to $ 737.435 during the past year
What is the PE ratio of Windtree Therapeutics?
The price to earnings ratio of Windtree Therapeutics is -0.39
What is the reporting currency for Windtree Therapeutics?
Windtree Therapeutics reports financial results in USD
What is the latest annual profit for Windtree Therapeutics?
The latest annual profit of Windtree Therapeutics is USD -5.49M
What is the registered address of Windtree Therapeutics?
The registered address for Windtree Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Windtree Therapeutics website address?
The website address for Windtree Therapeutics is www.windtreetx.com
Which industry sector does Windtree Therapeutics operate in?
Windtree Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RBNERobin Energy Ltd
$ 13.85
(313.43%)
101.81M
OPOceanPal Inc
$ 1.63
(125.45%)
80.28M
LGHLWLion Group Holding Ltd
$ 0.0052
(116.67%)
6.87M
NEONNeonode Inc
$ 16.83
(68.47%)
4.78M
ICONIcon Energy Corporation
$ 2.90
(62.01%)
59.04M
SBETSharpLink Gaming Inc
$ 9.2275
(-71.63%)
41.92M
AIHSSenmiao Technology Ltd
$ 0.381
(-63.01%)
16.8M
CHSNChanson International Holding
$ 0.22
(-60.00%)
15.15M
KWMK Wave Media Ltd
$ 2.91
(-50.43%)
2.59M
JZXNJiuzi Holdings Inc
$ 1.56
(-46.39%)
2.24M
HCTIHealthcare Triangle Inc
$ 0.0201
(-33.00%)
856.89M
GNLNGreenlane Holdings Inc
$ 0.0101
(-34.42%)
792.34M
CGBSCrown LNG Holdings Ltd
$ 0.1104
(31.43%)
788.42M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 12.655
(3.81%)
246.13M
NVDANVIDIA Corporation
$ 141.97
(-2.09%)
180.81M

WINT Discussion

View Posts
subslover subslover 4 days ago
Windtree Announces Transformational Agreement to Acquire Revenue Generating Environmental Services Business
Windtree continues its transformation entering the rapidly growing $85 billion US environmental services space

Refocused strategy is expected to generate $12 million in revenue over the next 12 months

Transaction expected to produce a profitable business with growth opportunities through a roll up strategy

Windtree continues to pursue partnership or sale of pharmaceutical assets to reduce costs

WARRINGTON, Pa., June 10, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a diversified company focused on revenue generation in multiple growing industries, today announced a significant step in its drive toward overall profitability through its entry into a binding agreement to acquire Titan Environmental Services, Inc. (“Titan”)(OTC: TESI), a waste management business with operations in Michigan.

As consideration for the transaction, Windtree will issue preferred shares and has secured debt financing to fund the transaction and working capital for the business. Titan Environmental Services will become Windtree Environmental Services (“Windtree Environmental”) and operate as a subsidiary of Windtree. Members of Titan’s current management team will be retained to leverage their extensive experience in the waste management industry. The transaction is expected to close in the 3rd quarter. In the event an agreement cannot be consummated, the Company is entitled to an $8.0 million breakup fee.

Over the last several months, Titan has undergone changes to its management and strategy, eliminating non-core assets, in order to focus on its waste management expertise to drive revenue. The United States waste collection market was valued at $85 billion in 2024 and has historically generated attractive EBITDA margins and free cash flow. In addition to the acquisition of Titan, the Company believes the fragmented waste management market may provide an opportunity to scale the business and provide additional top-line revenue growth and positive EBITDA contributions through additional acquisitions. Windtree Environmental intends to immediately begin the implementation and execution of a roll-up strategy to capitalize on this opportunity.

Under Windtree’s refined corporate strategy, the Company has, and continues to, pursue opportunities in a multitude of growing industries to drive toward overall profitability. The Company continues to evaluate options for its drug candidate pipeline in an effort to reduce costs and increase overall profitability.

“This transaction strategically aligns with our vision of diversifying our business model by increasing revenue and providing significant growth potential for the Company,” said Jed Latkin, Chief Executive Officer of Windtree. “We look forward to working with the Titan management and continuing to execute on our refined corporate strategy.”

About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is a diversified company focused on becoming a revenue-generating company in a multitude of growing industries to drive toward overall profitability.
👍️0
glenn1919 glenn1919 1 week ago
WINT..............................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 2 months ago
WINT, 10Q due Thursday 4/17
👍️0
nowwhat2 nowwhat2 3 months ago
Did somebody mention rveginas ?
👍️0
makinezmoney makinezmoney 3 months ago
$WINT: Who doesn't love Vaginal News

Am I right Ladies ???


GO $WINT
👍️0
glenn1919 glenn1919 3 months ago
WINT...................................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 3 months ago
Vaginal news followed up by compliance news this morning  $3.55 + 40% . Be wise low float 800k but offering comes eventually 
👍️0
glenn1919 glenn1919 3 months ago
WINT.......................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783
👍️0
gapole gapole 3 months ago
Power hour...wint at 2.16...will it get pumped at eod??
👍️0
makinezmoney makinezmoney 3 months ago
$WINT: We're going to $5 before EOD

You heard it here first....................... Don't be scared now


GO $WINT
👍️0
makinezmoney makinezmoney 3 months ago
$WINT; $3.40 babyyyyyyyyyyyyyyyyyyyyyyyyy

Whos havin a good time............ talk to me now


GO $WINT
👍️0
makinezmoney makinezmoney 3 months ago
$WINT: Bring on the $3 breaker baby


You know you wannnnaaaaaaaaaaaaaaaaaaaaaaaa

Do it for DADDY


GO $WINT
👍️0
makinezmoney makinezmoney 3 months ago
$WINT: Now 2.70 ....................

Holla back if you making money off my CALLOUTS !!!!!!!!!!!!!!!

Love to hear from you.

Keep on ROcking in the Free World............ while its still a Free World




GO $WINT
👍️0
glenn1919 glenn1919 3 months ago
WINT.........................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783
👍️0
makinezmoney makinezmoney 3 months ago
$WINT: Going on News...............




GO $WINT
👍️0
makinezmoney makinezmoney 3 months ago
$WINT: The bottom is in............ look at 200day chart

Shes gonna get to $3 today

GO $WINT
👍️0
makinezmoney makinezmoney 3 months ago
$WINT: BOoommmmmmmmmmmm.... now $2.20

Thar she blowwwwwwwwwssssssssssssss


GO $WINT
👍️0
glenn1919 glenn1919 3 months ago
WINT........................................................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
WINT EXPLOSION
👍️ 1
TrendTrade2016 TrendTrade2016 3 months ago
WINT POST SPLIT MOVE
👍️0
Monksdream Monksdream 4 months ago
WINT, new 52 week low
👍️ 1
getmoreshares getmoreshares 4 months ago
RS info -1 for 50- feb 20--Windtree Therapeutics, Inc. (NasdaqCM: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, announces that its board of directors has approved a 1-for-50 reverse stock split of the Company’s common stock. The Company’s stockholders approved the reverse stock split proposal at the Company’s Special Meeting of Stockholders held on February 3, 2025. The stockholders granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split.
The reverse stock split will become effective on February 20, 2025 at 5:00 p.m., Eastern Time (the “Effective Time”), and the Company’s common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) on February 21, 2025 at market open under the existing ticker symbol, “WINT.” The reverse stock split is intended to increase the price per share of the Company’s common stock to allow the Company to demonstrate compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq, among other benefits.
👍️0
big bambino big bambino 4 months ago
big uptick on GNS also 😅
👍️0
big bambino big bambino 4 months ago
nice move 😁
👍️0
glenn1919 glenn1919 4 months ago
WINT.............................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 4 months ago
.2530 + 58%
👍️0
valleybenedetto valleybenedetto 4 months ago
Jumped in today .125 heavy
👍️0
getmoreshares getmoreshares 4 months ago
great site- thanks RS 5 to 50 Vote Approved
👍️0
bigbux1 bigbux1 4 months ago
Scroll 9 down...https://dilutiontracker.com/app/reverse-split
👍️0
getmoreshares getmoreshares 4 months ago
RS approved- no ratio announced yet
👍️0
BigJuan BigJuan 4 months ago
$WINT Hmm reversal here starting? Maybe run before 2/3 meeting.
👍️0
big bambino big bambino 5 months ago
checked for reason on surge and nothing visible, even on website
👍️0
Mr. Zen Mr. Zen 6 months ago
today announced that Alexandre Mebazaa, MD, one of the world’s recognized leaders in cardiogenic shock, gave a well-received presentation highlighting the data on istaroxime from the recently completed Phase 2b SEISMiC B study in early cardiogenic shock due to heart failure. The presentation was given at the Cardiovascular Clinical Trials Conference in Washington, DC.

Dr. Alexandre Mebazaa is Professor of Medicine at Université Paris Cité (France), Chair of Department of Anesthesia & Critical Care and an expert in heart failure and cardiogenic shock. He is part of the task force that wrote the 2021 ESC/HFA Guidelines of Heart Failure and the 2023 addendum.
👍️ 1 🚀 1
Monksdream Monksdream 7 months ago
WINT, new 52 low
👍️0
Monksdream Monksdream 7 months ago
WINT 10Q due 11/11
👍️0
Mr. Zen Mr. Zen 7 months ago
Took another position here, this could very easily be a $30.00 stock in 2 years, patience pays.
👍️ 1
tw0122 tw0122 8 months ago
Ping pong .80s to $1s
👍️0
Mr. Zen Mr. Zen 8 months ago
This may be the bottom for a longer term play,if they are successful with phase three it will be a $30.00 +/- stock. IMO
👍 2
glenn1919 glenn1919 8 months ago
WINT.....................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 8 months ago
WINT take smaller gain .94s to $1.20 exit having trouble on bigger breakout to $1.40s
👍️0
tw0122 tw0122 8 months ago
1.11 test again
👍️0
tw0122 tw0122 8 months ago
WINT $1.11 breakout solid and $1.44
Up next 3m floater
👍️0
Mr. Zen Mr. Zen 8 months ago
Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the issuance of an istaroxime patent for Japan. The patent is entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF).” The claims are directed to intravenous administration of istaroxime using increased infusion times alone or in combination with other agents useful to treat AHF, thereby improving treatment of heart failure and diastolic relaxation when compared to conventional protocols. The application has been accorded Patent No. 7560134 with a registration date of September 24, 2024 and will expire in 2039.
👍️0
Monksdream Monksdream 8 months ago
WINT new 52 week low
👍️0
Monksdream Monksdream 8 months ago
WINT new 52=week low
👍️0
Roadtojourney Roadtojourney 8 months ago
Yup they pr only to dilute there share pos?? Imo
👍️0
Mr. Zen Mr. Zen 8 months ago
Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the trial design of its SEISMiC Phase 2b has been published by the European Society of Cardiology Heart Failure. The article is entitled, “Safety and efficacy of up to 60 hours of intravenous istaroxime in pre-cardiogenic shock patients: Design of the SEISMiC trial.” It can be found online in Wiley Online Library DIO: 10.1002/ehf2.15102. Results can be viewed at https://ir.windtreetx.com/corporate-presentation. The Heart Failure Society of America also shared the results.
👍️0
tw0122 tw0122 8 months ago
$1.26 + 36%
👍️0
tw0122 tw0122 8 months ago
Pump it
👍️0
Monksdream Monksdream 8 months ago
WINT anew 52 week low
👍️0

Your Recent History

Delayed Upgrade Clock